Risk-adjusted female breast cancer incidence rates in the United States

2012 ◽  
Vol 36 (2) ◽  
pp. 137-140 ◽  
Author(s):  
Ray M. Merrill ◽  
Arielle Sloan
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Female Breast Cancer ◽  
Incidence Rates ◽  
Female Breast ◽  
Cancer Incidence Rates

Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998

2003 ◽  
Vol 21 (1) ◽  
pp. 28-34 ◽  
Author(s):  
Christopher I. Li ◽  
Janet R. Daling ◽  
Kathleen E. Malone
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Incidence ◽  
Hormone Receptor ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Incidence Rates ◽  
Hormone Receptor Status ◽  
Receptor Status ◽  
Cancer Incidence Rates

Purpose: Between 1987 and 1998, breast cancer incidence rates rose 0.5%/yr in the United States. A question of potential etiologic and clinical importance is whether the hormone receptor status of breast tumors is also changing over time. This is because hormone receptor status may reflect different etiologic pathways and is useful in predicting response to adjuvant therapy and prognosis. Methods: Age-adjusted, age-specific breast cancer incidence rates by estrogen receptor (ER) and progesterone receptor (PR) status from 1992 to 1998 were obtained and compared from 11 population-based cancer registries in the United States that participate in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. Results: From 1992 to1998, the overall proportion of breast cancers that were ER-positive and PR-positive increased from 75.4% to 77.5% (P = .0002) and from 65.0% to 67.7% (P < .0001), respectively, continuing trends observed before 1992. These increases were limited to women 40 to 69 years of age. The proportions of ER-positive/PR-positive tumors increased from 56.7% to 62.3% (P = .0010) among 40- to 49-year-olds, from 58.0% to 63.2% (P = .0002) among 50- to 59-year-olds, and from 63.2% to 67.9% (P = .0020) among 60- to 69-year-olds. Conclusion: From 1992 to 1998, the proportion of tumors that are hormone receptor–positive rose as the proportion of hormone receptor–negative tumors declined. Because the incidence rates of hormone receptor–negative tumors remained fairly constant over these years, the overall rise in breast cancer incidence rates in the United States seems to be primarily a result of the increase in the incidence of hormone receptor–positive tumors. Hormonal factors may account for this trend.

scholarly journals An international comparison of male and female breast cancer incidence rates

2012 ◽  
Vol 132 (8) ◽  
pp. 1918-1926 ◽  
Author(s):  
Diana Ly ◽  
David Forman ◽  
Jacques Ferlay ◽  
Louise A. Brinton ◽  
Michael B. Cook
Keyword(s):  
Breast Cancer ◽  
International Comparison ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Female Breast Cancer ◽  
Incidence Rates ◽  
Male And Female ◽  
Female Breast ◽  
Cancer Incidence Rates

scholarly journals Breast cancer incidence among women of Branicevo region in the period 1991 - 2000

2004 ◽  
Vol 57 (9-10) ◽  
pp. 467-472 ◽  
Author(s):  
Sandra Sipetic ◽  
Vesna Petrovic ◽  
Zorica Milic ◽  
Hristina Vlajinac
Keyword(s):  
Breast Cancer ◽  
Incidence Rate ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Female Breast Cancer ◽  
Incidence Rates ◽  
Cancer Incidence Rate ◽  
Breast Cancer Incidence Rate ◽  
Female Breast ◽  
The World

Introduction Breast cancer is the most common type of cancer in women, the second leading cause of cancer death, and the third most common cancer overall, throughout the world. In 1996, 910.000 new cases were diagnosed worldwide (about 9% of all new cases). Over 50% of breast cancer incidence occurred in the developed world. The aims of this study were to study breast cancer incidence during 1991-2000 in the region of Branicevo and to analyze differences in incidence rate for breast cancer in two periods of time 1991-1991 and 1996-2000. Material and methods This was a descriptive study. Routine national incidence data were used from the Republic Statistical Office. The analysis was restricted to the region of Branicevo. Age adjustment of annual incidence rates was carried out using five-year intervals and the distribution of the World population by Sega as the standard. Results A total of 542 women affected with breast cancer were evidenced in the Region of Branicevo during the period 1991- 2000, accounting for 25.3% of all malignant cases. Over the studied ten-year period the average standardized incidence rate (1:100,000) for breast cancer was 27.4. Based on the average age-specific incidence rates (1:100,000) female breast cancer was least frequently evidenced in women up to 34 years of age, while it was most frequent in groups aged 45 - 49 and 70 - 74 years. Over the period 1991-1995, female breast cancer accounted for 32.0% and in the period 1996-2000 for 22.2% of all mlignancies, with the average standardized incidence rates (1:100,000) being 22.5% and 32.4%, respectively. Discussion The average standardized incidence rate (1:100,000) for breast cancer was 27.4, which is similar to the rates evidenced in Eastern European countries, such as Poland (38.7), Slovakia (34.5), Hungary (29.6), Romania (31.1), Belarus (24.7) and Russia (40.6). Increase of breast cancer incidence rate, evidenced in the Region of Branicevo, is also evidenced in most countries with previously low incidence rates. Increase of breast cancer incidence rate is also detected in our neighboring countries, Bulgaria and Slovenia. Conclusions An increasing trend of breast cancer incidence rate was evidenced in the Region of Branicevo over the period 1991 - 2000, partially due to well kept registries and partially due to actual increase in the number of patients affected with malignant diseases.

Regional Changes in Hormone Therapy Use and Breast Cancer Incidence in California From 2001 to 2004

2007 ◽  
Vol 25 (23) ◽  
pp. 3437-3439 ◽  
Author(s):  
Anthony S. Robbins ◽  
Christina A. Clarke
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Cancer Incidence ◽  
White Women ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Female Breast Cancer ◽  
Cancer Surveillance ◽  
California Health Interview Survey ◽  
Female Breast

Purpose Recently, an unprecedented 1-year 7% decrease in the overall incidence of invasive female breast cancer in the United States was reported. It has been suggested that the decrease resulted from the mass cessation of estrogen-progestin hormone therapy (EPHT) in 2002. We took advantage of California's unique population-based cancer surveillance resources to assess whether regional changes in breast cancer incidence observed between 2001 and 2004 correlated with regional changes in EPHT use between 2001 and 2003. Methods We obtained statewide cancer registry and California Health Interview Survey (CHIS) EPHT data for almost 3 million non-Hispanic white women age 45 to 74 years, residing in California's 58 counties. We examined trends in the age-adjusted incidence of invasive female breast cancer and compared these with trends in the use of EPHT, after grouping all California counties into three groups based on EPHT use in 2001. We also examined CHIS data on trends in screening mammography. Results In 2001, there were large regional differences in EPHT use and breast cancer incidence. From 2001 to 2004, incidence declined by 8.8% in the counties with the smallest EPHT reductions, by 13.9% in those with intermediate reductions, and by 22.6% in counties with the largest EPHT reductions. Between 2001 and 2003, CHIS data did not show any significant change in the proportion of women who reported having a mammogram in the previous 2 years. Conclusion These data support the hypothesis that changes in EPHT use in 2002 may be responsible for significant declines in breast cancer incidence between 2002 and 2003 and sustained through 2004.

Sign in / Sign up

Export Citation Format

Share Document